Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Instil Bio, Inc. (TIL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3000-0.0600 (-4.41%)
At close: 04:00PM EST
1.3300 +0.03 (+2.31%)
After hours: 06:21PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1’23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zacha

  • GlobeNewswire

    Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations of pre-clinical data and trial-in-progress for the ongoing ITIL-306 Phase 1 clinical trial using the CoStimulatory Antigen Receptor (CoStAR) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (

  • Benzinga

    Instil Bio Share Sink After Enrollment Pause In Cancer Therapy Trials

    Instil Bio Inc (NASDAQ: TIL) has voluntarily paused enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 and has notified regulatory authorities in the U.S., Canada, and the U.K. No regulatory agencies have notified the company of a clinical hold in its clinical trials. The voluntary pause was instituted following a recent decreased rate in the successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not success

Advertisement
Advertisement